Does one copy of HFE H63D usually cause clinically important iron overload?

At age 64, an isolated HFE H63D result should be interpreted as a low-risk genetic finding, not as a diagnosis of hereditary haemochromatosis or an explanation for iron overload.

Clinical evidence

• One H63D allele without C282Y is not generally considered hereditary haemochromatosis and does not independently increase the risk of clinically important iron overload. Cohort evidence is consistent: carriers may have modestly altered iron indices, but clinically significant iron-overload outcomes are rare.
• This should not be extrapolated from H63D homozygosity or C282Y/H63D compound heterozygosity, which are different genotypes with different clinical implications.
• If iron studies are abnormal, other contributors—including alcohol exposure, metabolic/fatty liver disease, inflammation, and other liver disorders—should be considered rather than attributing findings to H63D alone.

Iron-test interpretation

• Serum ferritin and transferrin saturation (TSAT) are the guideline-supported paired first tests. AASLD recommends HFE testing when TSAT is ≥45% or ferritin exceeds the reference range.
• Ferritin estimates iron stores but is an acute-phase reactant: inflammation and liver injury can raise it without hepatic iron overload. TSAT identifies increased circulating iron availability, but does not quantify liver iron or independently prove tissue iron excess.
• In people who are not HFE C282Y homozygotes, elevated ferritin and TSAT require confirmation of tissue iron—typically quantitative liver MRI, with biopsy reserved for selected circumstances—before diagnosing clinically important iron overload.

Mechanistic context

• H63D HFE can form stable complexes with transferrin receptor 1, unlike the more consequential defect associated with C282Y, supporting its comparatively mild biological effect.

Bottom line

• One H63D copy is very unlikely to cause clinically important iron overload by itself. Ferritin plus TSAT determine whether an iron-overload phenotype is plausible; abnormal results need clinical context and, when necessary, MRI confirmation rather than genotype-based treatment.